| 摘要: |
| 目的 系统评价氢吗啡酮或吗啡用于鞘内药物输注系统（IDDS）治疗癌痛的有效性及安全性。方法 检索中国知网（CNKI）、万方数据、维普网、CBM、PubMed、Cochrane Library、Ovid等中英文文献数据库，查找鞘内输注氢吗啡酮或吗啡治疗癌痛的随机对照试验（RCT），检索时限从建库至2023年8月31日。由2位研究者根据纳入、排除标准独立检索筛选文献、提取数据，并根据Cochrane偏倚风险评价工具对RCT进行质量评价，采用RevMan 5.4.1软件进行meta分析。结果 共纳入6篇RCT、544例患者，其中氢吗啡酮组282例、吗啡组262例。meta分析结果显示，两组在治疗后疼痛评分与暴发痛发生次数差异均无统计学意义（均P＞0.05）。与吗啡组相比，氢吗啡酮组恶心呕吐、便秘及嗜睡发生率均下降（P≤0.05），且氢吗啡酮组生活质量优于吗啡组（P＜0.05）。结论 经IDDS输注氢吗啡酮治疗癌痛的疗效与吗啡相当，氢吗啡酮在降低不良反应发生率、改善患者生活质量方面具有优势。 |
| 关键词: 癌性疼痛 鞘内药物输注系统 吗啡 氢吗啡酮 meta分析 |
| DOI：10.16781/j.CN31-2187/R.20230736 |
| 投稿时间：2023-12-14修订日期：2024-02-27 |
| 基金项目:海军军医大学（第二军医大学）第二附属医院2023年度教学成果立项培育项目（JXPY2023A12）． |
|
| Efficacy and safety of hydromorphone or morphine for cancer pain using intrathecal drug delivery system: a meta-analysis |
| LI Rongrong,YUAN Hongbin,WANG Yangyang,HE Xingying* |
(Department of Anesthesiology, The Second Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200003, China
* Corresponding author) |
| Abstract: |
| Objective To systematically evaluate the efficacy and safety of hydromorphone or morphine for cancer pain using intrathecal drug infusion system (IDDS). Methods Chinese and English literature databases, including CNKI, Wanfang, VIP, CBM, PubMed, Cochrane Library, and Ovid, were searched from inception to Aug. 31, 2023 to collect randomized controlled trials (RCTs) about intrathecal infusion of morphine or hydromorphone in treatment of cancer pain. Two reviewers independently screened literature and extracted data according to the inclusion and exclusion criteria, and evaluated the quality of RCTs using a Cochrane bias risk assessment tool. Then, meta-analysis was performed using RevMan 5.4.1 software. Results A total of 6 RCTs, involving 544 patients, were enrolled. Among them, there were 282 cases in the hydromorphone group and 262 cases in the morphine group. The meta-analysis results showed that there were no significant differences in pain score or number of breakthrough pain episodes between the 2 groups after treatment (all P＞0.05). Compared with the morphine group, the incidence rates of nausea and vomiting, constipation, and somnolence were significantly decreased in the hydromorphone group (P≤0.05), and the quality of life was significantly higher (P＜0.05). Conclusion The efficacy of hydromorphone administered by IDDS for cancer pain is comparable to morphine; hydromorphone has advantages in reducing adverse reactions and improving quality of life of patients. |
| Key words: cancer pain intrathecal drug delivery system morphine hydromorphone meta-analysis |
